Phase Ia study of anti-NAPI2B antibody–drug conjugate lifastuzumab vedotin DNIB0600A in patients with non–small cell lung cancer and platinum-resistant ovarian cancer

  1. Gerber, D.E.
  2. Infante, J.R.
  3. Gordon, M.S.
  4. Goldberg, S.B.
  5. Martín, M.
  6. Felip, E.
  7. Garcia, M.M.
  8. Schiller, J.H.
  9. Spigel, D.R.
  10. Cordova, J.
  11. Westcott, V.
  12. Wang, Y.
  13. Shames, D.S.
  14. Choi, Y.
  15. Kahn, R.
  16. Dere, R.C.
  17. Samineni, D.
  18. Xu, J.
  19. Lin, K.
  20. Wood, K.
  21. Royer-Joo, S.
  22. Lemahieu, V.
  23. Schuth, E.
  24. Vaze, A.
  25. Maslyar, D.
  26. Humke, E.W.
  27. Burris, H.A.
  28. Erakutsi egile guztiak +
Aldizkaria:
Clinical Cancer Research

ISSN: 1557-3265,  1078-0432

Argitalpen urtea: 2020

Alea: 26

Zenbakia: 2

Orrialdeak: 364-372

Mota: Artikulua

DOI: 10.1158/1078-0432.CCR-18-3965 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus